Therapeutic drug monitoring of anti-TNF drugs: an overview of applicability in daily clinical practice in the era of treatment with biologics in juvenile idiopathic arthritis (JIA).

Nassar-Sheikh Rashid, A; Schonenberg-Meinema, D; Bergkamp, S C; Bakhlakh, S; de Vries, A; Rispens, T; Kuijpers, T W; Wolbink, G; van den Berg, J M

Nassar-Sheikh Rashid, A; Schonenberg-Meinema, D; Bergkamp, S C; Bakhlakh, S; de Vries, A; Rispens, T; Kuijpers, T W; Wolbink, G; van den Berg, J M.

Afiliação

Nassar-Sheikh Rashid A; Zaans Medical Center, Zaandam and Emma Children's Hospital, Amsterdam UMC, Pediatric Immunology, Rheumatology and Infectious Diseases, University of Amsterdam, Amsterdam, The Netherlands. a.nassar@amsterdamumc.nl.
Schonenberg-Meinema D; Emma Children's Hospital, Amsterdam UMC, Pediatric Immunology, Rheumatology and Infectious Diseases, University of Amsterdam, Amsterdam, The Netherlands.
Bergkamp SC; Emma Children's Hospital, Amsterdam UMC, Pediatric Immunology, Rheumatology and Infectious Diseases, University of Amsterdam, Amsterdam, The Netherlands.
Bakhlakh S; Emma Children's Hospital, Amsterdam UMC, Pediatric Immunology, Rheumatology and Infectious Diseases, University of Amsterdam, Amsterdam, The Netherlands.
de Vries A; Department of Immunopathology, Sanquin Diagnostic Services Amsterdam, Amsterdam, The Netherlands.
Rispens T; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam, The Netherlands.
Kuijpers TW; Emma Children's Hospital, Amsterdam UMC, Pediatric Immunology, Rheumatology and Infectious Diseases, University of Amsterdam, Amsterdam, The Netherlands.
Wolbink G; Department of Immunopathology, CLB Sanquin Amsterdam and Department of Rheumatology, Jan van Breemen Institute Amsterdam, Amsterdam, The Netherlands.
van den Berg JM; Emma Children's Hospital, Amsterdam UMC, Pediatric Immunology, Rheumatology and Infectious Diseases, University of Amsterdam, Amsterdam, The Netherlands.

Pediatr Rheumatol Online J ; 19(1): 59, 2021 Apr 29.

Article em En | MEDLINE | ID: mdl-33926495

Assuntos

Adalimumab; Anticorpos Anti-Idiotípicos/sangue; Artrite Juvenil; Monitoramento de Medicamentos/métodos; Etanercepte; Infliximab; Inibidores do Fator de Necrose Tumoral; Adalimumab/imunologia; Adalimumab/uso terapêutico; Anticorpos Monoclonais/imunologia; Artrite Juvenil/tratamento farmacológico; Artrite Juvenil/imunologia; Criança; Tomada de Decisão Clínica; Relação Dose-Resposta Imunológica; Etanercepte/imunologia; Etanercepte/uso terapêutico; Feminino; Humanos; Infliximab/imunologia; Infliximab/uso terapêutico; Masculino; Conduta do Tratamento Medicamentoso; Seleção de Pacientes; Inibidores do Fator de Necrose Tumoral/imunologia; Inibidores do Fator de Necrose Tumoral/uso terapêutico

Palavras-chave

Anti-TNF drug trough levels; Anti-drug antibodies; Biologics; Children; Juvenile idiopathic arthritis (JIA)

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Artrite Juvenil / Anticorpos Anti-Idiotípicos / Monitoramento de Medicamentos / Adalimumab / Infliximab / Etanercepte / Inibidores do Fator de Necrose Tumoral Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google